xalkori
pfizer europe ma eeig - crizotinib - carcinom, pulmonar non-celulă mică - agenți antineoplazici - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.
alunbrig
takeda pharma a/s - brigatinib - carcinom, pulmonar non-celulă mică - agenți antineoplazici - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.
prabegin capsule 100 mg
egis pharmaceuticals plc - pregabalinum - capsule - 100 mg
prabegin capsule 150 mg
egis pharmaceuticals plc - pregabalinum - capsule - 150 mg
prabegin capsule 200 mg
egis pharmaceuticals plc - pregabalinum - capsule - 200 mg
prabegin capsule 225 mg
egis pharmaceuticals plc - pregabalinum - capsule - 225 mg
prabegin capsule 25 mg
egis pharmaceuticals plc - pregabalinum - capsule - 25 mg
prabegin capsule 300 mg
egis pharmaceuticals plc - pregabalinum - capsule - 300 mg
prabegin capsule 50 mg
egis pharmaceuticals plc - pregabalinum - capsule - 50 mg
prabegin capsule 75 mg
egis pharmaceuticals plc - pregabalinum - capsule - 75 mg